Adaptive Biotechnologies (ADPT) Revenue (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Revenue data on file, last reported at $70.9 million in Q1 2026.

• Quarterly Revenue rose 35.14% year-over-year to $70.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $295.4 million (up 55.87% YoY) and the FY2025 annual result came in at $277.0 million, up 54.77% from the prior year.
• Revenue declined to $70.9 million in Q1 2026 per ADPT's latest filing, from $71.7 million in the prior quarter.
• The five-year high for Revenue was $94.0 million in Q3 2025, with the low at $7.7 million in Q2 2023.
• Average Revenue over 5 years is $49.5 million, with a median of $46.4 million recorded in 2024.
• Year-over-year, Revenue plunged 82.36% in 2023 and jumped 460.91% in 2024.
• Adaptive Biotechnologies' Revenue stood at $55.2 million in 2022, then dropped by 17.05% to $45.8 million in 2023, then climbed by 3.66% to $47.5 million in 2024, then surged by 51.04% to $71.7 million in 2025, then fell by 1.13% to $70.9 million in 2026.
• Business Quant data shows ADPT's Revenue at $70.9 million in Q1 2026, $71.7 million in Q4 2025, and $94.0 million in Q3 2025.